Researchers from The University of Texas Medical Branch at Galveston have developed the first vaccine for chikungunya fever made from an insect-specific virus that doesn’t have any effect on people, making the vaccine safe and effective. The newly developed vaccine quickly produces a strong immune defense and completely protects mice and nonhuman primates from disease when exposed to the chikungunya virus.
The findings are detailed in Nature Medicine.
“This vaccine offers efficient, safe and affordable protection against chikungunya and builds the foundation for using viruses that only infect insects to develop vaccines against other insect-borne diseases,” said UTMB professor Scott Weaver, senior author of this paper.
Chikungunya is a mosquito-borne virus that causes a disease characterized by fever and severe joint pain, often in hands and feet, and may include headache, muscle pain, joint swelling, or rash. Some patients will feel better within a week but many develop longer-term joint pain that can last up to years. Death is rare but can occur.
Traditionally, vaccine development involves tradeoffs between how quickly the vaccine works and safety. Live-attenuated vaccines that are made from weakened versions of a live pathogen typically offer rapid and durable immunity but reduced safety. On the other hand, the inability of inactivated vaccines to replicate enhances safety at the expense of effectiveness, often requiring several doses and boosters to work properly. There may be a risk of disease with both of these vaccine types, either from incomplete inactivation of the virus or from incomplete or unstable weakening of the live virus that is only recognized when rare vulnerable individuals develop disease.
To overcome these tradeoffs, the researchers used the Eilat virus as a vaccine platform since it only infects insects and has no impact on people. The UTMB researchers used an Eilat virus clone to design a hybrid virus-based vaccine containing chikungunya structural proteins.
The Eilat/Chikungunya vaccine was found to be structurally identical to natural chikungunya virus. The difference is that although the hybrid virus replicates very well in mosquito cells, it cannot replicate in mammals.
Within four days of a single dose, the Eilat/Chikungunya candidate vaccine induced neutralizing antibodies that lasted for more than 290 days. The antibodies provided complete protection against chikungunya in two different mouse models. In nonhuman primates, Eilat/Chikungunya elicited rapid and robust immunity – there was neither evidence of the virus in the blood nor signs of illness such as fever after chikungunya virus infection.
Learn more: UTMB researchers develop first chikungunya vaccine from virus that does not affect people
[osd_subscribe categories=’chikungunya’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CHIKUNGUNYA”‘]
Receive an email update when we add a new CHIKUNGUNYA article.
The Latest on: Chikungunya vaccine
[google_news title=”” keyword=”Chikungunya vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Chikungunya vaccine
- Health officials issue warning over outbreaks of virus: 'Poses a significant risk'on May 9, 2024 at 3:00 am
It's part of a concerning trend of increasing incidence rates for vector-borne diseases. Health officials issue warning over outbreaks of virus: 'Poses a significant risk' first appeared on The Cool ...
- Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updateson May 6, 2024 at 9:00 pm
Financial Results andProvides Corporate UpdatesQ1 financial highlightsTotal revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidanceCash position of ...
- Chikungunya Virus and Prospects for a Vaccineon May 5, 2024 at 5:00 pm
Chikungunya virus (CHIKV ... However, there are several vaccine candidates in preclinical and clinical development. Past vaccine development included the 181/clone25 strain, which relies on ...
- Vaccine Partners Turn Rivals With First Shot for Advancing Viruson May 4, 2024 at 11:00 pm
Two European partners will soon be vying for dominance in a new battleground: vaccines to protect travelers against a painful viral illness transmitted by mosquitoes.
- Chikungunya Newson May 4, 2024 at 5:00 pm
The findings could lead to a universal therapy or vaccine for the ... Dec. 2, 2021 — Dengue, Chikungunya, and Zika viruses have all been recorded in Mexico; however, recent diagnostic advances ...
- Valneva Gears Up To Launch The First Ever Chikungunya Virus Vaccineon May 1, 2024 at 3:00 am
Ixchiq is a single shot live attenuated vaccine for the prevention of chikungunya virus vaccine which provided immunity to over 98% of participants in a phase 3 clinical trial. The vaccine was well ...
- Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidateon April 29, 2024 at 6:41 am
Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the end of the first half of 2024 to support a potential FDA approval of the vaccine in ...
- Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chikungunya Vaccine Candidateon April 29, 2024 at 6:03 am
“We are pleased to advance our chikungunya vaccine candidate into the registration phase and look forward to working with the regulators in our efforts to bring this novel product to the marke ...
- After coming up short in COVID, Valneva focuses on chikungunya vaccine launchon April 18, 2024 at 5:02 am
And now, most importantly for Valneva, is the launch of its new vaccine for the chikungunya virus. The shot, which was endorsed by the FDA in November of last year and recommended for use by the ...
via Bing News